A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2018

Primary Completion Date

November 4, 2018

Study Completion Date

November 4, 2018

Conditions
Alzheimer's Disease
Interventions
DRUG

AGN-242071

AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.

DRUG

Placebo

Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.

DRUG

Donepezil

Donepezil 10 mg as prescribed by the physician as per standard of care.

DRUG

Memantine

Memantine as prescribed by the physician as per standard of care.

Trial Locations (6)

90806

Collaborative Neuroscience, Long Beach

90807

Alliance Research, Long Beach

91945

Synergy Research Centers, Lemon Grove

92614

Irvine Center for Clinical Research, Irvine

92705

Syrentis Clinical Research, Santa Ana

94105

ATP Clinical Research, Costa Mesa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY